Editorial Board About Us

Arie S Belldegrun

All articles from this author are listed below.

Volume 6, Number 1 Reviews in Urology

Primary Leiomyosarcoma of the Inferior Vena Cava Presenting as a Renal Mass

Arie S Belldegrun John S Lam Oleg Shvarts Ken-ryu Han

Inferior vena cava Nephrectomy Leiomyosarcoma

Volume 8, Number 3 Meeting Reviews

Best of the 2006 AUA Annual Meeting

Meeting Review

Arie S Belldegrun John P Stein John P Mulhall Tobias Klatte Michael E Aldridge Li-Ming Su Shachi Tyagi J Curtis Nickel Danil V Makarov Ellen Shapiro Alan W Partin Michael B Chancellor Victor W Nitti Jacob Rajfer Claus G Roehrborn Michael K Brawer

Highlights from the 2006 Annual Meeting of the American Urological Association May 20–25, 2006 Atlanta, GA

Prostate cancer Infertility Benign prostatic hyperplasia Bladder cancer Kidney cancer Lower urinary tract symptoms Bladder exstrophy Overactive bladder Interstitial cystitis Stress urinary incontinence Peyronie’s disease Spina bifida Neurogenic bladder Erectile dysfunction Chronic pelvic pain syndrome Chronic prostatitis Tumor markers Androgen replacement therapy Ejaculatory dysfunction Anorectal malformations Renal stones Robotic-assisted radical prostatectomy

Volume 8, Number 1 Review Articles

Surveillance Strategies for Renal Cell Carcinoma Patients Following Nephrectomy

Management Update

Arie S Belldegrun Arnold I Chin Robert A Figlin John S Lam

Kidney Recurrence Nephrectomy Cancer Renal Surveillance

Volume 9, Number 2 Review Articles

Understanding the Natural Biology of Kidney Cancer: Implications for Targeted Cancer Therapy

Treatment Update

Arie S Belldegrun Allan J Pantuck Tobias Klatte Mark D Kleid

During the past several decades, there has been a significant increase in the understanding of the biology, clinical behavior, and prognostic factors of renal cell carcinoma (RCC). Such progress has led to greater sophistication in the diagnosis and classification of RCC. Here, we review recent advances in our knowledge of the biologic characteristics of RCC that have resulted in notable achievements in staging, prognosis, patient selection, and treatment. [Rev Urol. 2007;9(2):47-56]

Angiogenesis Genetics Molecular markers Targeted treatment Tumor-node-metastasis classification

Volume 11, Number 2 Meeting Reviews

Best of the 2009 AUA Annual Meeting

Highlights From the 2009 Annual Meeting of the American Urological Association, April 25-30, 2009, Chicago, IL

Arie S Belldegrun B Shuch F Pouliot Ellen Shapiro Alan W Partin Michael B Chancellor Stacy Loeb J Curtis Nickel Dean G Assimos Claus G Roehrborn Michael K Brawer Naoki Yoshimura

Prostate cancer screening Obesity Benign prostatic hyperplasia Lower urinary tract symptoms Vesicoureteral reflux Nephrolithiasis Stress urinary incontinence Inflammation Silodosin Hormonal therapy Tumor markers TMPRSS2ERG 4-Kallikrein panel Botulinum toxin type A Male voiding dysfunction Benign prostatic specific antigen Roux-en-Y gastric bypass surgery Genitourinary pain index UPOINT clinical phenotype system Nephron-sparing surgery Watchful waiting Laparoscopy for adrenal cortical carcinoma Partial adrenalectomy Urethral trauma Pediatric urethral stricture Enteric urologic surgery

Volume 14, Number 3 Review Articles

Systemic Therapy for Metastatic Renal Cell Carcinoma: A Review and Update

Management Update

Fairooz F Kabbinavar Arie S Belldegrun Allan J Pantuck Dennis J Slamon Karim Chamie Joshua E Logan Edward N Rampersaud Geoffrey A Sonn

An in-depth understanding of metastatic renal cell carcinoma (mRCC) is important so that practitioners can make informed evidenced-based decisions with patients to optimize not only quantity of life but quality of life as well. Therefore, this review focuses on the biology of mRCC as it relates to targets for therapy, as well as on the small molecules rationally designed with these targets in mind. In addition, anticipated emerging therapies are highlighted, including the new tyrosine kinase inhibitors axitinib and tivozanib, as well as new immune-based therapies such as dendritic cell-based vaccines and antibodies. We also briefly review recent reports from the emerging field of predicting drug response based on molecular markers. And finally, management of metastatic non-clear cell RCC histologies are discussed focusing on available evidence to direct decision making when assessing therapeutic options. [Rev Urol. 2012;14(3/4):65-78 doi: 10.3909/riu0562] © 2013 MedReviews®, LLC

Metastatic renal cell carcinoma Tyrosine kinase inhibitors Dendritic cell-based vaccines